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Notch signaling is considered a rational target in the therapy of several cancers, particularly those 
harbouring Notch gain of function mutations, including T-cell acute lymphoblastic leukemia (T-ALL). 
Although currently available Notch-blocking agents are showing anti-tumor activity in preclinical 
studies, they are not effective in all the patients and often cause severe side-effects, limiting their 
widespread therapeutic use. Here, by functional and biological analysis of the most representative 
molecules of an in house library of natural products, we have designed and synthetized the chalcone-
derivative 8 possessing Notch inhibitory activity at low micro molar concentration in T-ALL cell lines. 
Structure-activity relationships were afforded for the chalcone scaffold. Short term treatments with 
compound 8 resulted in a dose-dependent decrease of Notch signaling activity, halted cell cycle 
progression and induced apoptosis, thus affecting leukemia cell growth. Taken together, our data 
indicate that 8 is a novel Notch inhibitor, candidate for further investigation and development as an 
additional therapeutic option against Notch-dependent cancers.
The Notch signaling pathway is an inter-cellular communication system driving many biological processes start-
ing from stem cells self-renewal up to cell differentiation, proliferation and survival in different tissues and in 
a wide spectrum of organisms1. The mammalian Notch family includes four highly evolutionarily conserved 
trans-membrane receptors (Notch1–4) and five canonical ligands (Jagged-1, and -2, Delta-like-1, -3 and -4).
Notch proteins are synthetized as immature precursors in Endoplasmic Reticulum. Following the proteolytic 
cleavage by Furin-like convertase (S1 cleavage) in the trans-Golgi, mature Notch receptors accumulate on cell sur-
face as heterodimers composed of the Notch extracellular domain (NECD), the transmembrane domain (NTM) 
and the intracellular domain (NICD), held together by non-covalent interactions. Notch signaling-induced 
trans-activation is triggered by the contact between a membrane-associated ligand on the signal-sending cell and 
a Notch trans-membrane receptor on the signal-receiving cell. The interaction with the ligand predisposes the 
Notch receptor to the cleavage by ADAM metalloproteases (S2 cleavage), that allows the subsequent cleavage by 
gamma secretase (GS) complex (S3 cleavage). S3 cleavage leads to the release of active NICD from the membrane, 
which translocates to the nucleus and regulates the transcription of specific target genes2.
Deregulated Notch signaling due to either gene mutation or amplification, or to post-translational modi-
fications, contributes to development and progression of different solid and hematological cancers, including 
T-cell acute lymphoblastic leukemia (T-ALL)3, by directly driving the expression of several oncogenes and cell 
cycle-related factors4–7, and indirectly by cross-talking with other critical oncogenic signaling pathways8–12.
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T-ALL arises in the thymus from the malignant transformation of T-cell progenitors and is one of the most 
aggressive blood cancers, which accounts for approximately 15% of paediatric and 25% of adult acute lymphoblas-
tic leukemia. Although T-ALL prognosis has gradually improved, thanks to the available chemotherapeutic pro-
tocols, to date the fate of patients with primary therapy-resistant or relapsed leukemia remains unfavourable13, 14.
Several Notch-blocking agents have been developed up to preclinical research and a number of them have 
been moved to clinical trials for the therapy of Notch-driven tumors, including T-ALL15. In this respect, it is 
worth noting that the most promising pharmacologic approach to block Notch signaling relies in the suppres-
sion of the S3 cleavage operated by GS, which leads to the generation of the NICD. Unfortunately, as revealed by 
clinical trials, the potential clinical applications of GS inhibitors (GSIs) is limited by primary resistance and/or by 
severe side effects, especially those occurring within the gastrointestinal tract16.
In the last decade, naturally occurring chemotypes re-emerged as lead candidates for anticancer therapy17–20 
and, a number of natural products affecting Notch gene expression have been suggested as potential anti-cancer 
Notch inhibitors21–23.
In the present study, an in house library composed of about one thousand natural products and their chem-
ical derivatives24–27 was clustered based on fingerprints and substructure search through a cheminformatics 
approach28. The representative compounds of the eight most populated clusters have been screened by func-
tional, biological and biochemical investigations, for their strength in impairing Notch signaling activity and cell 
growth in Notch-dependent human T-ALL cell lines. The 2′,3,4,4′-tetrahydroxychalcone (molecule C, butein) 
emerged as valuable hit compound, thus emphasizing the relevance of the chalcone scaffold in Notch inhibition. 
However, the molecule contains a catechol moiety, which is susceptible for oxidation both in vitro and in vivo, 
providing possible off-target effects29. Therefore, cycles of design-synthesis-bioassay and testing in vitro were 
established to optimize the potency of initial chalcone hit, and to eliminate or mask the undesirable chemical 
feature. Structure-activity relationships (SAR) were afforded, and a novel potent Notch inhibitor, namely 8, was 
identified and characterized. Compound 8 short term and low dose treatments inhibited the endogenous Notch 
signaling activity and suppressed cell growth of several human T-ALL cell lines by promoting apoptosis and G1 
cell cycle arrest.
Interestingly, compound 8 inhibits Notch signaling without interfering with S2 and S3 proteolytic cleavages, 
depending on ADAM and GS, respectively. Overall, our findings suggest molecule 8 as a novel Notch inhibitor 
candidate for further investigation and development.
Results
Butein is a naturally occurring Notch signaling inhibitor. An in house library of about one thousand 
natural products and their derivatives was used as source of potential modulators of the Notch signaling. Notably, 
natural products have long been used as medicines and remedies for human disease, and in the modern era are 
considered as a relevant source of lead compounds for drug discovery19, 20, 25, 30. Accordingly, our in house library 
is a valid source of chemotypes for the modulation of biomolecular targets, and it has been successfully screened 
in silico and in vitro for the identification of hit and lead compounds in previous early-stage drug discovery 
projects24–27.
Here, to concentrate experimental efforts on a relatively low number of molecules, and to explore as much 
as possible the chemical and scaffold space of the library, we envisaged to test in vitro a representative subset of 
molecules. To this end, a diversity-oriented random selection (DORS) of compounds was performed by means of 
a clustering algorithm, which is based on a combination of fingerprints and common substructure (adapted from 
that developed by Stahl and Mauser)28. The representative molecules of the eight most abundant clusters were 
selected for this work (Table 1), based on physical availability at the time of the experiments, hit-like features31, 
and chemical diversity criteria.
As a useful experimental model to screen putative Notch inhibitors we utilized DND41 human T-ALL cells 
which harbour constitutively activated Notch1 signaling due to activating Notch1 gene mutations3 and express 
high levels of Notch36. In addition, the growth of DND41 cells is sensitive to the inhibition of Notch signaling by 
the treatment with GSI32.
To identify novel Notch modulating agents, we evaluated the effects on the endogenous Notch1 activation in 
DND41 human cells after 36 hrs of exposure to increasing doses of selected molecules (0, 1, 5, 10, 20, 50 μM). 
Treatments with compounds D, E, F and G did not influence the expression of the activated domain of Notch1, 
as revealed by western blot by using the antibody against the Valine 1744 (N1VAL), whereas the exposure to 
compounds A, B and H resulted in its decrease only at high doses (between 20 μM and 50 μM). On the other 
hand, compound C showed the highest Notch inhibiting activity as revealed by decreased immunoreactivity to 
N1VAL at low micro molar concentration (between 5 μM and 10 μM) (Fig. 1). Effectiveness of Notch signaling 
modulation was further confirmed by the decreased levels of expression of the intracellular domain of Notch3 
receptor (N3ICD).
To investigate the biological implications of the above compounds, we then tested their ability to exert 
anti-proliferative effects. Thus, we evaluated the growth sensitivity of DND41 T cells to these compounds by 
determining the half-maximal growth inhibitory concentration (IC50) by MTS cell assay. In keeping with its high-
est Notch blocking activity, the compound C was the most powerful molecule in inhibiting cell growth with IC50 
value of 7.79 ± 1.73 μM (Table 1 and Fig. S1).
By contrast, compounds B and H showed a weaker growth inhibitory activity with IC50 values of 
13.89 ± 2.70 μM and 22.64 ± 1.89 μM, respectively, while compounds A, D, E, F and G did not influence consid-
erably DND41 cell growth up to 50 μM (Table 1 and Fig. S1). Cross-comparative assessment of the above data led 
us to select, among the screened compounds, the chalcone C as the most powerful Notch inhibitor.
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Design and synthesis of chemical derivatives of butein. The chalcone scaffold emerged as a promis-
ing tool to inhibit Notch signaling, and was therefore selected for further investigations. With the aim of increas-
ing the potency of the hit compound C, to remove the undesired catechol moiety29, and to afford SAR that may 
facilitate further development as well as the understanding of the molecular determinants for Notch inhibition, 
compound C derivatives 1, 2, 3, 4, 5, 5a, 6a, 7, 7a, 8, 8a and 9 were designed and synthesized (Fig. 2).
The general strategy employed to synthesize chalcones in excellent yield was based on the Claisen-Schmidt 
condensation as reported previously33 and illustrated in Fig. 3.
Functional and biological evaluation of the Notch signaling inhibitory activity in T-ALL of the 
newly synthesized chalcones. To probe the effectiveness of the above twelve derivatives of chalcone C, 
we investigated, in a dose-dependent manner at concentrations of 0, 1, 5, 10, 20, 50 μM, their potency as Notch 
signaling inhibitors in DND41 cells. Among them, compound 8 revealed improved potency and specificity of 
action compared to chalcone C, as it decreased N1VAL and N3ICD protein expression levels at the lowest micro 
molar doses (between 1 μM and 5 μM). In contrast, all the remaining synthetic derivatives modulated N1VAL and 
N3ICD expression levels at higher doses than the hit chalcone C (Fig. 4). Accordingly, dose–response cell prolif-
eration assay proved that compound 8 was the most effective molecule in impairing DND41 T-cell growth, with 
an IC50 value of 1.92 μM ± 0.14 μM. All the other chemical derivatives were 10–20 times weaker than compound 
8, as they showed IC50 values higher than 11 μM (Fig. 2). Substantial inhibition of cell growth was also reflected in 
molecule 8-treated cells growth curve (Fig. S2).
Given the high power of action at low micro molar concentration of compound 8, the subsequent functional 
and biological comparisons between compound 8 and fourteen newly-synthesized compounds were performed 
including two lower doses to the above showed dose response assays (0.5 μM and 2.5 μM).
Among the newly synthesized derivatives of compound 8, molecules 16 and 17 showed the strongest Notch 
signaling inhibitory activity in terms of potency in impairing endogenous Notch activity in DND41 cells, in a 
range of concentrations comparable to those shown by compound 8 (2.5 μM) (Fig. S3a). The treatments with 
the remaining derivatives of 8 resulted in weaker inhibition of Notch signaling activity, as all of them decreased 
Compound Chemical structure IC50 ± S.D. (μM)
A >50
B 13.89 ± 2.70
C 7.79 ± 1.73
D >50
E >50
F >50
G >50
H 22.64 ± 1.89
Table 1. Structure and inhibitory activity of natural compounds A–H. IC50 values were determined towards 
DND41 cells at 36 hrs incubation times. Data represent mean of values for triplicates ± standard deviations 
(S.D.).
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N1VAL and N3ICD expressions at doses higher than 5 μM (Fig. S3a). Moreover, the subsequent close compar-
ison of the Notch inhibitory potency at 2.5 μM between compounds 8, 16 and 17 confirmed, among them, 8 as 
the strongest Notch signaling inhibitor (Fig. S4). In addition, compound 8 confirmed the strongest biological 
activity as reflected by the cell growth curves and the relative IC50 values, in response to increasing doses of all the 
synthetic derivatives (Figs S3b and 2). Indeed, all derivatives of 8, including 16 and 17, showed IC50 values higher 
than 13 μM (Fig. 2). Interestingly, among tested molecules, 8b provided the poorer effects on both Notch sign-
aling inhibition and cell growth as showed by the western blots against N1VAL and N3ICD, and by the growth 
curve and IC50 values (Figs S3 and 2).
SAR of chalcone derivatives as Notch inhibitors. Functional and biological analysis of the naturally 
occurring chalcone C and its newly synthesized twenty-six chemical derivatives highlighted the molecule 8 as 
the most active Notch inhibitor in T-ALL. SAR were elaborated at three structural levels: ring A, ring B and the 
α,β-unsaturated carbonyl system of the chalcone scaffold, and were graphically sketched in Fig. 5.
Concerning ring A, methylation of the hydroxyl group at position 2′ improved the inhibitory effect on cell 
proliferation only when ring B is not substituted with hydroxyl group at position 4. In this condition, the presence 
of methoxyl group at position 4′ provides higher activity than the hindered tetrahydropyranyl protecting group. 
Therefore, since chalcone 8 is the most potent Notch inhibitor of the series, the 2′ and 4-hydroxy groups seem to 
act synergistically. Based on this evidence, the mono substitution of ring A in different positions (14, 15 and 17) 
originates weaker chalcones compared to the 2′,4′-substitutions (8 and 16). Finally, mono substituted derivatives 
showed similar inhibitory effect on cell viability, even though the 4′-methoxy group (17) drastically reduced the 
N1VAL and N3ICD expression in a comparable extent to 8, and in contrast to what observed for 2′-substituted 
chalcones (14 and 15) (Figs 5 and S3).
Notably, the potency of chalcone derivatives seems to be significantly dependent from the pattern of substitu-
tions to ring B. In fact, comparing chalcones bearing the same ring A, the hydroxyl group improved the activity of 
the molecules particularly when it is inserted at position 4 of ring B, which proved to be critical for reducing both 
cell proliferation and Notch expression (8) (Figs 5 and S3).
Finally, the reduction of the double bond in the α, β-unsaturated carbonyl system (8b) completely abrogates 
biological effects, thus suggesting that the restricted flexibility of the spacer in chalcones is required to keep the 
pharmacophoric phenyl rings A and B at the suitable distance to provide potent Notch inhibition.
Compound 8-induced Notch signaling inhibition suppresses several leukemia cell lines growth 
by promoting apoptosis and G1 cell cycle arrest. To preliminarily investigate if compound 8 inhibits 
Notch signaling by suppressing endogenous GS or ADAM metalloprotease enzymatic activities, we compared the 
effects of compound 8 with the GSI DAPT or with the ADAM10 specific inhibitor GI254023X (GI) on the tran-
scriptional activity of a membrane-tethered Notch1 intracellular domain, including the aminoacidic sequence of 
the region surrounding the ADAM cleavage site (N1ICD-ΔE)34. HEK cells were transiently co-transfected with 
a Notch responsive 12X CSL-Luciferase reporter and the construct encoding N1ICD-ΔE. Transfected cells were 
then exposed for 36 hrs to increasing doses of compound 8, DAPT or GI. Compound 8 treatments did not affect 
the transcriptional activity. Conversely, as expected, both DAPT and GI exposure decreased the promoter lucif-
erase activity in N1ICD-ΔE co-transfected cells (Fig. S5). Overall, our results revealed that compound 8 does not 
act by inhibiting GS- or ADAM-dependent Notch cleavages.
Figure 1. Chalcone C inhibits endogenous Notch signaling activation in DND41 T-ALL cells. Activated Notch1 
receptor domain (N1VAL) and Notch3 intracellular domain (N3ICD) expressions in DND41 T-ALL cell lines 
in response to 36 hrs of different doses exposure to eight molecules (named A–H) representative of the in house 
library consisting of one thousand natural compounds. β-actin is used as loading control. Uncropped Western 
blots related to this figure are displayed in Fig. S13.
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We next explored, the possibility that compound 8 affects Notch receptor transport to the membrane through 
the Golgi. To this aim, we investigated the surface expression of Notch1 and Notch3 receptors upon treatments 
with compound 8 or DAPT. DND41 cells treated with compound 8 show slight increased Notch1 surface expres-
sion, when compared to the vehicle-treated cells, while DAPT treatments resulted in greater surface Notch1 
receptor accumulation, due to the S3 blockade (Fig. S6). On the other hand, both treatments compound 8 and 
DAPT, decreased Notch3 surface expression in DND41 cells (Fig. S6). Notably, decreased Notch3 protein surface 
expression in DND41 cells treated with compound 8 is paralleled by decreased Notch3 gene expression upon 
compound 8 treatments in DND41 cell lines, in which Notch3 is a Notch1 target gene35 (Fig. S7).
Overall, the data above suggested compound 8 as the most promising Notch-blocking agent among the mol-
ecules screened, and in order to exclude cell-line-specific effects, we extended the analyses to additional T-ALL 
cell lines. Confirming its effectiveness on Notch signaling inhibition, 36 hrs of treatment with molecule 8, as well 
Figure 2. Structure and inhibitory activity of chalcone derivatives 1–17. IC50 values were determined towards 
DND41 cells at 36 hrs incubation times. Data represent mean of values for triplicates ± standard deviations 
(S.D.). aAll double bonds are in E configuration.
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as with DAPT, utilized as a positive control, decreased in a dose dependent manner the level of expression of 
N1VAL in DND41 and KOPTK1 and of N3ICD in TALL-1 cell lines characterized by constitutively active Notch1 
or Notch3 signaling36, 37, respectively (Figs 4, 6a and S8).
Consistently, compound 8-dependent Notch inhibition in DND41, KOPTK1 and TALL-1 cells correlated with 
the significant endogenous mRNA reduction of the known Notch target genes HES138, DELTEX139, c-MYC4 and 
NOTCH34 (Figs 6b and S7) and the growth inhibition at low doses (KOPTK1: IC50 = 0.91 ± 0.06 μM and TALL-1: 
IC50 = 0.29 ± 0.02 μM).
Notably, 36 hrs of DAPT exposures up to 50 μM did not affect the proliferation of T-ALL cell lines (DND41: 
IC50 = >50 μM; KOPTK1: IC50 = >50 μM; TALL-1: IC50 = >50 μM). Interestingly, compound 8 and DAPT, 
did not affect cell proliferation in immortalized non-tumorigenic human keratinocyte HaCat cells in which 
Notch signaling acts as onco-suppressor40. Indeed, although compound 8 and DAPT treatments in HaCat cells 
decreased N1VAL protein expression in a dose dependent manner (Figs 6c and S8), none of them was able to 
exert substantial cell growth inhibitory effects (8: IC50 = 48.61 ± 8.06 μM; DAPT: IC50 = >50 μM). Consistently, 
compound 8 did not affect cell cycle progression and apoptosis rate in the same cells (Fig. S9).
Finally, based on the observed dose-dependent growth inhibition linked to compound 8 treatments in sev-
eral T-ALL cell lines, we investigated biological processes downstream to 8-dependent Notch signaling inhi-
bition. We assessed, by flow cytometry analysis (FACS) after 7AAD staining, the effects of 36 hrs of treatment 
with compound 8 on cell cycle progression in DND41, KOPTK1 and TALL-1 cells. We observed a significant 
accumulation of cells in G1 phase following compound 8-treatment in all the cell lines analysed (Figs 7a and S10). 
Concomitantly, we detected a substantial decreased expression of proteins involved in G1-S checkpoint progres-
sion, Cyclin D3 and the related kinases CDK4, accompanied by increased expression of the cyclin-dependent 
kinase inhibitor p27 which act as an inhibitor of G1-S transition (Fig. 7b). These data are consistent with the G1 
cell cycle arrest previously observed after Notch1 pharmacological blockage by GSI treatment in Notch-driven 
T-cell leukaemia32, 41. In addition, we detected, by FACS analysis after Annexin V and 7AAD staining, a significant 
induction of apoptosis in human T-ALL cell lines after treatment with molecule 8 (Fig. 7c and S11). These data 
were further confirmed by the increased levels of the cleaved poly ADP-ribose polymerase PARP (Fig. 7d).
Notably, DAPT treatment, utilized as a positive control, was not able to affect cell cycle progression or apop-
tosis rate in T-ALL cells analysed (Fig. S12). This observation is in line with the GSI-dependent marked growth 
arrest previously reported in long terms of exposures (3–7 days) and not described in short terms treatments in 
T-ALL contexts3, 42, 43.
Finally, to further evaluate whether 8-induced anti-growth effects in T-ALL are via Notch signaling inhibition, 
we treated with compound 8 DND41 cells transduced with retroviruses encoding murine N1ICD (mICN1) or 
with the relative empty retroviral vector (empty). Strength of transduction was evaluated by western blot against 
N1ICD (Fig. 8a). mICN1 enforced expression partially rescued the anti-proliferative effects induced by com-
pound 8 in DND41 cells when compared to the control cells (Fig. 8b).
Discussion
Increasing evidence indicates that the selective targeting of signaling pathways controlling Cancer Stem Cells 
(CSCs) self-behavior is a promising strategy to improve the effectiveness of the conventional anti-cancer chemo- 
and radio-therapies.
In the last few years, Notch signaling has been demonstrated to be essential in CSCs maintenance and 
self-renewal in several human tumors including T-ALL44, 45, thus providing the rationale for developing novel 
Notch inibitor-based therapies to prevent drug-resistance, recurrence and metastasis in solid and hematologic 
cancers, characterized by deregulated Notch signaling15. Current clinical investigations with regard to Notch 
Figure 3. General synthesis of chalcone derivatives 1–17. The synthetic pathway is based on the Claisen-
Schmidt condensation reaction. Selected compounds 5a, 7a–8a, 11a, 14a–17a were deprotected to give the 
corresponding chalcones.
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inhibition in cancer are mostly focused on small molecules with GSI activity or on monoclonal antibodies 
(mABs) targeting specific Notch receptors and ligands46, 47, but although favourable outcomes are expected, both 
approaches show drawbacks that limit their widespread therapeutic use. Actually, GSIs are not Notch selective 
as they block the cleavage of a wide variety of trans-membrane proteins48. In addition, not all T-ALL harbouring 
Notch1 activating mutations are sensitive to GSI36, 43 and the treatment with GSIs often causes serious adverse side 
effects in patients49, 50. On the other hand, although mAbs have highly specific target selectivity, they show poor 
Figure 4. Compound 8 is a potent Notch signaling inhibitor. Endogenous N1VAL and N3ICD protein 
expression levels in DND41 T-ALL cells in response to 36 hrs of different doses of exposure to the twelve 
C-derivative molecules (named 1, 2, 3, 4, 5, 5a, 6a, 7, 7a, 8, 8a and 9). β-actin is used as a loading control. 
Uncropped Western blots related to this figure are displayed in Fig. S14.
Figure 5. SAR of the chalcone derivatives as Notch inhibitors in T-ALL. Three structural levels were identified 
by analyzing functional and biological data: ring A, ring B and α, β-unsaturated carbonyl system of the chalcone 
scaffold.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 2213  | DOI:10.1038/s41598-017-02316-9
Figure 6. Compound 8 counteracts Notch signaling in T-ALL cell contexts. (a) N1VAL, N3ICD and β-actin 
protein expression levels in response to 36 hrs of different doses of compound 8 exposures in KOPTK1 and 
TALL-1. (b) Relative DELTEX1 (DTX1), HES1 and c-MYC gene expression levels in response to 36 hrs 
of treatment with molecule 8 in KOPTK1, TALL-1 and DND41 cells. In detail, KOPTK1 and DND41 cell 
were treated with 2.5 μM, while TALL-1 cell with 1 μM of compound 8. Data represent mean values ± S.D. 
normalized to GAPDH of three independent experiments. *P < 0.05; **P < 0.01; ns not significant. (c) N1VAL 
and β-actin protein expression levels in response to 36 hrs of dose dependent manner of compound 8 exposures 
in HaCat cells. Uncropped Western blots related to this figure are displayed in Fig. S15.
Figure 7. Compound 8-treatment halts cell cycle in G1 phase and induces apoptosis in human T-ALL cells. 
T-ALL cell lines were treated for 36 hrs with compound 8 or with vehicle alone (DMSO) as indicated: DND41 
and KOPTK1 with 2.5 μM of 8 and TALL-1 with 1 μM of 8. Cell cycle progression was investigated by FACS 
analysis of DNA content after 7AAD staining. (a) Histograms show the mean of cell percentage ± S.D. in G1 
versus S-G2-M phases of cell cycle of four independent experiments. *P < 0.05. (b) Protein expression levels 
of Cyclin D3, CDK4 and p27 in DND41, KOPTK1 and TALL-1 cells treated with compound 8 or with vehicle 
alone (DMSO). Compound 8-induced apoptosis rate and cell death were investigated by FACS analysis after 
Annexin V and 7AAD staining in DND41, KOPTK1 and TALL-1 cells. (c) Histograms show the mean of 
cell percentage ± S.D. of early and late apoptotic cells of at least four independent experiments. *P < 0.05; 
**P < 0.01; ns not significant. (d) Compound 8-induced effects on PARP activation in DND41, KOPTK1 
and TALL-1 cells as shown by the protein expression levels of the precursor (FL PARP) and the cleaved PARP 
(C PARP). β-actin is used as loading control. Uncropped Western blots related to this figure are displayed in 
Fig. S16.
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tissue and cell membrane penetration and mostly act on target antigens secreted by or expressed on the surface 
of tumor cells. Given the number of Notch deregulated signaling-related diseases and cancers, other than T-ALL 
leukemia, there is an urgent need to develop novel efficient and safe Notch-blocking therapies.
Following a DORS approach in silico, we identify here the 2′,3,4,4′-tetrahydroxychalcone (C) as a profitable Notch 
signaling inhibiting agent. Consistently with previous reports showing anti-proliferative properties of chalcones against 
numerous cancer cells51, 52, including acute lymphoblastic leukemia53, 54, we found a strict correlation between the 
C-induced Notch signaling blockage and the relative cellular response. Indeed, we found that short time exposure to 
molecule C substantially suppresses in a dose-dependent manner Notch1 activation and cell growth in human T-ALL 
cell lines exerting its biochemical and biological activities starting from concentration between 5 and 10 μM.
Accordingly, the chalcone scaffold emerged as a valuable tool for the design and synthesis of novel chalcone 
derivatives endowed with higher potency and most suitable pharmacological properties than the hit compound C. 
Twenty-six chalcones were synthesized and tested in vitro, highlighting the molecule 8 as the most potent Notch 
blocking agent of the series. Compound 8, as well DAPT, suppresses endogenous Notch signaling activity in a 
short term treatment and in a low micro-molar range of exposure, as revealed by the decrease of the levels of the 
Notch activated domain and of the expression of several known Notch target genes in different human T-ALL cell 
models. Notably, we demonstrated that compound 8 does not interfere with the GS or ADAM activity, nor, at least 
in DND41 cells, with the early phases of receptor maturation process ending with the cell-surface localization of 
Notch receptor, thus encouraging future in-depth investigations to address its molecular mechanism of action.
Previous studies demonstrated that deregulated Notch signaling activation is linked to the uncontrolled 
growth of T-ALL cells and, consistently Notch inhibition by long term GSI treatments results in cell cycle arrest 
and apoptosis of GSI-sensitive cell lines3, 42, 43.
Here, we show that Notch inhibition, induced by short time exposure to chalcone–derived molecule 8 at low 
micro molar concentrations, results in anti-proliferative and pro-apoptotic effects in several human T-ALL cells, 
which were reverted by N1ICD overexpression, thus demonstrating that Notch1 inhibition is responsible, at least 
in part, of the growth inhibitory effect.
Notably, the data presented in our work suggest that compound 8 and the GSI DAPT are not pharmacologi-
cally equivalent and display significant differences in Notch inhibition.
In DND41, KOPTK1 and TALL-1 cells, short term exposures to compound 8 arrested G1/S cell-cycle pro-
gression further supported by the reduction of Cyclin D3 and CDK4 levels, both known to be regulated by Notch 
signaling to promote transition through the cell cycle during T-ALL leukemogenesis41. Moreover, in keeping with 
Dohda and colleagues data, which demonstrated that deregulated Notch signaling in T-ALL promotes cell cycle 
progression by maintaining low levels of expression of the anti-proliferative p2755, we observed that 8-induced G1 
cell cycle arrest in DND41, KOPTK1 and TALL-1 cells combined with increased expression levels of p27, further 
supporting the compound 8 anti-cancer activity leading to apoptosis of human T-ALL cells.
In summary, our results propose the chalcone derivative 8 as a novel and potent Notch inhibitor endowed with 
a naturally occurring scaffold, and provide novel guidelines for future development of chalcone-based bioactive 
Notch blocking agents, useful in the treatment of T-ALL and other cancers characterized by activated Notch sig-
naling as single agents, or in combination with standard anti-cancer drugs.
Methods
Cheminformatics. A clustering algorithm adapted from that developed by Stahl and Mauser28 was generated 
in Python language by using the OpenEye Python Toolkit (OpenEye Toolkits 2015. OpenEye Scientific Software, 
Santa Fe, NM. http://www.eyesopen.com). The algorithm was then used to cluster the in house library of natural 
products and their derivatives by following a DORS approach. In particular, a cutoff of 0.6 was used for Tanimoto-
based comparison of maccs166 type fingerprints, while a cutoff of 0.8 was used for the Raymond score56 during 
the analysis of maximum common substructures28.
Figure 8. Compound 8 impairs cell growth through Notch inhibition. (a) Western blot analysis on GFP-sorted 
DND41 cells transduced with the mICN1 or with the empty control retroviruses by using antibodies against 
C-terminal domain of Notch1 and β-actin. (b) Effect of compound 8 treatment on the growth of GFP-sorted 
DND41 transduced with mICN1 or with the empty retroviruses for the times indicated. The relative cell 
number in percentage at each time point represents the mean value of triplicates normalized to the cell number 
at 96 hrs of DMSO treatment. Bars indicate S.D. *P < 0.05; **P < 0.01. Uncropped Western blots related to this 
figure are displayed in Fig. S17.
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Source and characterization of natural compounds A – H. All the tested compounds A–H are 
known structures, which belong to our in house library of natural products. Chemical identity of compounds 
A–H was assessed by re-running NMR experiments, which proved to be in agreement with the literature data 
reported below for each compound. The purity of compounds A, B, E and F, checked by reversed-phase HPLC 
under the chromatographic conditions reported below, was always higher than 95%. Compound A (taxifolin 
or (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one) showed NMR spectra iden-
tical to the literature57. Compound B (4-hydroxy-isocordoin or (E)-1-[2,4-dihydroxy-3-(3-methylbut-2-enyl)
phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one) showed NMR spectra identical to the literature58. Compound 
C (butein or (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one)59 was purchased from 
Sigma-Aldrich (487-52-5), and used without further modification. Compound D (xanthotoxin: 9-methoxyfuro-
[3,2-g]chromen-7-one)60, 61 was purchased from Sigma-Aldrich (298-81-7), and used without further modifica-
tion. Compound E (columbianetin or (8R)-8-(2-hydroxypropan-2-yl)-8,9-dihydrofuro[2,3-h]chromen-2-one) 
showed NMR spectra identical to the literature62. Compound F (1-hydroxy-7-methoxy-9H-xanthen-9-one) 
showed NMR spectra identical to the literature63. Compound G (usnic acid or 2,6-diacetyl-7,9-dihydroxy-8,9
b-dimethyldibenzofuran-1,3-dione)64 was purchased from Sigma-Aldrich (7562-61-0), and used without fur-
ther modification. Compound H (galangin or 3,5,7-trihydroxy-2-phenylchromen-4-one)65 was purchased from 
Sigma-Aldrich (548-83-4), and used without further modification.
Chemistry. All reagents were commercial and were used without further purification. Chromatography was 
carried out on silica gel (230–400 mesh). All reactions were monitored by thin-layer chromatography (TLC), and 
silica gel plates with fluorescence F254 were used. Purity of natural products, and the characterization of synthetic 
chalcones are reported in the Supplementary Materials section.
General procedure for the protection of differently substituted 3- or 4-hydroxybenzaldehydes as tetrahy-
dropyranyl ethers. A differently substituted 3- or 4- hydroxybenzaldehyde (16 mmol) and pyridinium 
p-toluenesulfonate (0.40 mmol) (Sigma-Aldrich 232238) were dissolved in CH2Cl2 (dichloromethane) (75 ml) 
and 3,4-dihydro-α-pyran (2.23 ml, 0.05 mmol) (Sigma-Aldrich 37350) in CH2Cl2 (75 ml) was added dropwise. 
The reaction mixture was stirred at room temperature for 24 hrs, then washed with water, dried over Na2SO4 and 
evaporated in vacuo. The residue was purified by silica gel flash chromatography with n-Hexane: EtOAc = 9: 1 
(v/v) as eluent, to obtain the corresponding tetrahydropyranyloxybenzaldehyde.
General procedure for the protection of differently substituted 4′-hydroxyacetophenones as tetrahydropyranyl 
ethers. A differently substituted 4′-hydroxyacetophenone (16 mmol) and pyridinium p-toluenesulfonate 
(0.40 mmol) were dissolved in CH2Cl2 (75 ml) and 3,4-dihydro-α-pyran (2.23 ml, 0.05 mmol) in CH2Cl2 (75 ml) 
was added dropwise. The reaction mixture was stirred at room temperature for 24 hrs, then washed with water, 
dried on Na2SO4 and evaporated in vacuo. The residue was purified by silica gel flash chromatography with 
n-Hexane: EtOAc = 9: 1 (v/v) as eluent, to obtain the corresponding tetrahydropyranyloxyacetophenone.
General procedure for the synthesis of chalcones. A solution of a suitable acetophenone (0.01 mol) and a suitable 
benzaldehyde (0.01 mol) were dissolved in EtOH (ethanol) and partially dehydrated barium hydroxide octahy-
drate (0.01 mol) was slowly added. The reaction mixture was stirred for 24 hrs at room temperature and then 
concentrated in vacuo. After water had been added, the mixture was neutralized with 2 M HCl and extracted with 
EtOAc (ethyl acetate). The organic layer was collected, dried over Na2SO4 and evaporated in vacuo. The residue 
was purified by silica gel flash chromatography with n-Hexane: EtOAc = 9: 1 (v/v) as eluent, to afford the corre-
sponding chalcone 1–4, 9–10, 12–13, 5a-8a, 11a, 14a–17a.
General procedure for the deprotection of chalcones. Protected chalcone 5a, 7a–8a, 11a, 14a–17a (0.25 mmol) 
and p-toluenesulfonic acid (0.03 mmol) were dissolved in MeOH (20 ml). The reaction mixture was stirred for 
24 hrs at room temperature and then evaporated in vacuo. After water had been added, the mixture was neu-
tralized with 5% NaHCO3 and extracted with EtOAc. The organic layer was collected, dried over Na2SO4 and 
evaporated in vacuo. Purification of the residue via silica gel flash chromatography (n-Hexane: EtOAc = 9: 1 (v/v)) 
afforded the corresponding chalcone 5, 7–8, 11, 14–17.
Catalytic hydrogenation of 8. After two vacuum/nitrogen cycles to replace the air inside the reaction tube, com-
pound 8 (100 mg, 0.37 mmol) and 10% Pd/C (98 mg) in dry EtOAc (10 mL) were vigorously stirred at room 
temperature under 1 atm of H2 for 24 hrs. The reaction mixture was filtered through a membrane filter (Millipore, 
Millex-LH, 0.45 mm) and the filtrate was concentrated giving compound 8b in quantitative yield.
Cell lines and treatments. DND41, KOPTK1 cells were cultured in RPMI-1640 (Gibco, Carlsbad, CA, 
USA) containing 10% fetal bovine serum. TALL-1 cells were maintained in RPMI-1640 (Gibco, Carlsbad, CA, 
USA) containing 20% fetal bovine serum. HEK and HaCat cells were cultured in Dulbecco’s modified Eagle’s 
medium (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum. Cells were treated with: DAPT (565770; 
Calbiochem, Darmstadt, Germany), GI254023X (SML0789, Sigma-Aldrich, St Louis, MO, USA), compounds of 
natural origins A–H or the synthetics molecules 1–17 for the indicated concentrations and times of exposure.
Immunoblot analysis. Protein extracts preparation was described elsewhere66. Blots were incubated with 
primary antibodies against: Notch1Val1744 (2421; Cell Signaling Technology, Beverly, MA, USA), Notch3 
(2889; Cell Signaling Technology, Beverly, MA, USA), Notch1 (sc-6014-R; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), Cyclin D3 (sc-182; Santa Cruz Biotechnology, Santa Cruz, CA, USA), CDK4 (sc-260; Santa 
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Cruz Biotechnology, Santa Cruz, CA, USA), p27 (3688; Cell Signaling Technology, Beverly, MA, USA), PARP 
(9542; Cell Signaling Technology, Beverly, MA, USA) and β-actin (sc-47778; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA); followed by hybridization with Antibodies HRP conjugated: anti‐rabbit (sc-2004; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), or anti-mouse (sc-2005; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Real-time PCR. Total RNA was extracted from cells using TRIzol (15596018; Invitrogen, Carlsbad, CA, 
USA) as described previously67. 100–1.000 ng of total RNA was reverse transcribed using High Capacity cDNA 
Reverse Transcription Kit (4368814; Applied Biosystems, Foster City, CA, USA) according to the manufactur-
er’s protocol. Real-time PCR was performed using the ViiA™ 7 Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA). Taqman Gene Expression Master Mix and Taqman Gene Expression Assays for HES1 
(Hs00172878_m1), cMYC (Hs00905030_m1), DELTEX1 (Hs01092201_m1), NOTCH3 (Hs00166432_m1) and 
GAPDH (Hs02758991_g1) were purchased from Applied Biosystems, Foster City, CA, USA. Relative quantifi-
cation was carried out using the comparative ΔΔCt method. GAPDH expression was used to normalize mRNA 
levels.
Statistical analysis. Mean values and standard deviations were calculated to estimate the degree of data var-
iation, as detailed in the figure legends. The results were analyzed by using two-tailed Student’s t-test to calculate 
the statistical data significance.
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